CA-LINKSYS
24.5.2022 17:02:58 CEST | Business Wire | Press release
Linksys , a global leader in home and business WiFi networking solutions, today announced two new WiFi 6 mesh systems designed to deliver peak wireless performance for all at-home needs including remote working, streaming content, multi-user gaming and more. The Linksys Hydra 6 and Linksys Atlas 6 are Linksys’ newest entry-level dual-band products in the company's family of WiFi 6 mesh systems and come at the most affordable prices to date for the brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005310/en/
“There is an increased need for wireless connectivity that can handle the influx of devices on home networks, and deliver reliable, secure and private connections,” said Alan Cohen, VP of Marketing and Head of Product at Linksys. “Our mission is to connect everyone securely and through the launch of these systems, we provide our customers with two new options for fast speed, coverage, and connectivity at an affordable price point.”
Linksys Atlas 6 – Our Most Affordable WiFi 6 Mesh System to Date
The Linksys Atlas 6 is the newest whole-home mesh system in Linksys’ portfolio of products. Speed and performance at an affordable price, the Linksys Atlas 6 is ideal for hybrid work, online gaming, 4K UHD streaming, and more. The dual-band router works best with internet service plans up to a gigabit. Each Node has three 1Gbps Ethernet LAN ports for connecting wired devices to wireless networks and provides access to 160MHz channels for superfast wireless connections.
The Linksys Atlas 6 is available in three configurations. The 1-pack supports up to 25 devices and covers ~2,000 square feet, the 2-pack supports up to 50 devices and covers ~4,000 square feet, and the 3-pack supports up to 75 devices and up to ~6,000 square feet.
Linksys Hydra 6 – Dramatically Faster, Robust, and Reliable Connectivity
The Linksys Hydra 6 delivers high-speed wireless data for up to 25 devices over 2,000 square feet. The Linksys Hydra 6 WiFi 6 dual-band mesh router delivers dramatically faster, robust, and reliable wireless connections. Ideal for super smooth 4K UHD streaming, video conferencing, online gaming, and more. The router works best with internet service plans up to a gigabit. It provides 160 MHz channels for superfast wireless connections and has four 1 GbE Ethernet ports to connect wired devices such as gaming devices, television, DVR, and more to the wireless network.
Additional Features and Benefits for the Linksys Atlas 6 and Hydra 6
- Fast to set up. Easy to manage. – The Linksys App makes it simple to set up your WiFi network and you can control and monitor your WiFi from anywhere.
- Linksys Intelligent Mesh™ Technology – Dynamically optimize speeds and maximize the use of all bands to reduce congestion, latency and buffering.
- Security and privacy you can trust – Protect your home with automatic software updates so your network is always secure and up to date. Parental controls and separate guest networks keep devices safe.
- Peace of mind – Linksys products pass 25 quality tests, are backed by a 3-year warranty, and have 24/7 tech support.
- Grow as needed – When your family, home and needs grow, your WiFi should grow with you. Add more nodes to expand coverage for stronger connection and to handle more devices as needed.
- Robust. Stable. Reliable. – Built with the Qualcomm® Immersive Home 214 Platform users can expect great connectivity throughout the home.
Availability and Imagery
The Linksys Hydra 6 will be available beginning early summer in the US for MSRP $179.99 on Linksys.com and in select retailers; global availability to follow in the second half of 2022.
The Linksys Atlas 6 will be available beginning early summer in the US for MSRP $149.99 (1-pack), $279.99 (2-pack), and $349.99 (3-pack) on Linksys.com; global availability to follow in the second half of 2022.
Images of the Atlas 6 and Hydra 6 can be found here .
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home 214 Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005310/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom